Deciphera Pharmaceuticals (NASDAQ:DCPH) released its quarterly earnings data on Thursday. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13), Fidelity Earnings reports.
Shares of DCPH stock opened at $25.50 on Friday. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.53 and a beta of 3.27. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $45.61. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06.
In related news, Director James Arthur Bristol sold 18,883 shares of the stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $28.04, for a total value of $529,479.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $30.00, for a total value of $45,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 198,426 shares of company stock worth $5,247,846. Insiders own 20.61% of the company’s stock.
A number of research firms recently commented on DCPH. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd. Leerink Swann decreased their target price on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating on the stock in a research report on Friday, November 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 target price on shares of Deciphera Pharmaceuticals in a research report on Thursday, December 20th. Finally, B. Riley downgraded Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $42.67.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: QQQ ETF
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.